LabGenomics Co. Ltd (084650) - Cash Flow Conversion Efficiency
Based on the latest financial reports, LabGenomics Co. Ltd (084650) has a cash flow conversion efficiency ratio of -0.034x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-6.41 Billion ≈ $-4.35 Million USD) by net assets (₩188.67 Billion ≈ $127.86 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of LabGenomics Co. Ltd to measure how many days the company can operate on defensive assets alone.
LabGenomics Co. Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how LabGenomics Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
LabGenomics Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of LabGenomics Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bloomsbury Publishing Plc
LSE:BMY
|
0.004x |
|
Viji Finance Limited
NSE:VIJIFIN
|
0.017x |
|
Adya Inc
V:ADYA
|
0.087x |
|
Methanor
PA:ALMET
|
13.794x |
|
Realfiction Holding AB
ST:REALFI
|
-0.154x |
|
Citra Nusa Holdings Bhd
KLSE:5104
|
0.006x |
|
Nitro Games Oyj
ST:NITRO
|
0.317x |
|
Gafisa S.A
SA:GFSA3
|
-0.084x |
Annual Cash Flow Conversion Efficiency for LabGenomics Co. Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of LabGenomics Co. Ltd from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see LabGenomics Co. Ltd market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩216.31 Billion ≈ $146.59 Million |
₩-12.99 Billion ≈ $-8.81 Million |
-0.060x | -665.89% |
| 2023-12-31 | ₩228.14 Billion ≈ $154.61 Million |
₩2.42 Billion ≈ $1.64 Million |
0.011x | -96.82% |
| 2022-12-31 | ₩209.33 Billion ≈ $141.86 Million |
₩69.87 Billion ≈ $47.35 Million |
0.334x | -19.46% |
| 2021-12-31 | ₩157.72 Billion ≈ $106.88 Million |
₩65.36 Billion ≈ $44.29 Million |
0.414x | -27.12% |
| 2020-12-31 | ₩81.54 Billion ≈ $55.26 Million |
₩46.37 Billion ≈ $31.43 Million |
0.569x | +442.57% |
| 2019-12-31 | ₩30.42 Billion ≈ $20.61 Million |
₩3.19 Billion ≈ $2.16 Million |
0.105x | +418.90% |
| 2018-12-31 | ₩30.10 Billion ≈ $20.40 Million |
₩608.03 Million ≈ $412.05K |
0.020x | +142.71% |
| 2017-12-31 | ₩22.35 Billion ≈ $15.14 Million |
₩-1.06 Billion ≈ $-716.24K |
-0.047x | -146.58% |
| 2016-12-31 | ₩25.04 Billion ≈ $16.97 Million |
₩2.54 Billion ≈ $1.72 Million |
0.102x | -5.37% |
| 2015-12-31 | ₩22.15 Billion ≈ $15.01 Million |
₩2.38 Billion ≈ $1.61 Million |
0.107x | -27.59% |
| 2014-12-31 | ₩21.24 Billion ≈ $14.39 Million |
₩3.15 Billion ≈ $2.13 Million |
0.148x | -- |
About LabGenomics Co. Ltd
LabGenomics Co., Ltd. engages in the research and development of biotechnology products in South Korea. It is also involved in the sale of diagnostic devices. The company was founded in 2002 and is based in Seongnam-si, South Korea.